Table 1.
Factor | Division | Whole set (313 patients) | Subset (227 patients) | ||
n | Percentage | n | Percentage | ||
Age | ≤40 | 34 | 10.9 | 25 | 11.0 |
>40 | 279 | 89.1 | 202 | 89.0 | |
Menopausal status | Pre | 104 | 33.2 | 76 | 33.5 |
Post | 203 | 64.9 | 147 | 64.8 | |
Unknown | 6 | 1.9 | 4 | 1.8 | |
Tumor grade | 1 | 5 | 1.6 | 4 | 1.8 |
2 | 101 | 32.3 | 71 | 31.3 | |
3 | 191 | 61.0 | 144 | 63.4 | |
Unknown | 16 | 5.1 | 8 | 3.5 | |
Tumor size, cm | 0–2 | 100 | 31.9 | 71 | 31.3 |
> 2–5 | 173 | 55.3 | 131 | 57.7 | |
> 5 | 35 | 11.2 | 22 | 9.7 | |
Unknown | 5 | 1.6 | 3 | 1.3 | |
Pathological ER status | Negative | 72 | 23.0 | 54 | 23.8 |
Positive | 234 | 74.8 | 169 | 74.4 | |
Unknown | 7 | 2.2 | 4 | 1.8 | |
Lymphovascular invasion | Negative | 49 | 15.7 | 33 | 14.5 |
Positive | 244 | 78.0 | 184 | 81.1 | |
Unknown | 20 | 6.4 | 10 | 4.4 | |
Percentage of positive nodes | 0–50 | 121 | 38.7 | 89 | 39.2 |
>50–99.9 | 142 | 45.4 | 95 | 41.9 | |
100 | 50 | 16.0 | 43 | 18.9 | |
Number of positive nodes | 4–9 | 235 | 75.1 | 175 | 77.1 |
≥10 | 78 | 24.9 | 52 | 22.9 | |
Histology | Ductal | 279 | 89.1 | 210 | 92.5 |
Lobular | 34 | 10.9 | 17 | 7.5 | |
Adjuvant chemotherapy | No | 155 | 49.5 | 107 | 47.1 |
Yes | 158 | 50.5 | 120 | 52.9 | |
Adjuvant hormonal therapy | No | 104 | 33.2 | 78 | 34.4 |
Yes | 209 | 66.8 | 149 | 65.6 | |
Adjuvant radiotherapy | No | 70 | 22.4 | 50 | 22.0 |
Yes | 243 | 77.6 | 177 | 78.0 | |
Mastectomy | No | 2 | 0.6 | 1 | 0.4 |
Complete | 217 | 69.3 | 154 | 67.8 | |
Partial | 94 | 30.0 | 72 | 31.7 |
Data are presented for the 313-patient test set cohort, and for the 227-patient subgroup in which expression data were available for each of the eight immunohistochemical biomarkers assessed. Percentages are rounded.